Advertisement
A or RVTY or WAT
Which Stock Would AI Choose? Agilent Technologies (A) vs. Revvity (RVTY) vs. Waters Corporation (WAT) Stock Comparison
Key Takeaways
- Agilent Technologies (A), Revvity (RVTY), and Waters Corporation (WAT) operate in the life sciences and analytical instruments sector, with overlapping exposure to laboratory and diagnostic markets.
- Recent market activity shows varied performance, with RVTY delivering stronger year-to-date returns compared to A and WAT amid broader sector dynamics.
- All three companies reported first-quarter results that generally met or exceeded expectations, supporting stable sentiment in recent weeks.
- Upcoming second-quarter earnings releases for RVTY and WAT in early August, alongside Agilent’s third-quarter update later in the month, represent key near-term catalysts.
- Valuation sensitivity to growth in pharma and biotech spending remains a common factor influencing relative positioning across the group.
- Market sentiment reflects cautious optimism tied to product approvals and new instrument launches rather than broad sector rotation.
Introduction
Agilent Technologies (A), Revvity (RVTY), and Waters Corporation (WAT) represent established players in the life sciences tools and diagnostics space. This comparison examines their recent stock behavior, business drivers, and relative positioning for traders and investors focused on sector-specific exposure. Market participants seeking to understand performance differences amid evolving demand for analytical instruments and laboratory solutions may find the analysis relevant. The review draws on observable metrics and developments to highlight contrasts without projecting future outcomes.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, diagnostics, and services primarily for life sciences, applied chemicals, and diagnostics markets. In recent market activity, the stock has traded in a relatively narrow range, with year-to-date returns around 2.3% as of late July 2026. First-quarter fiscal 2026 results showed revenue of $1.84 billion, reflecting 10% year-over-year growth and a modest beat on expectations. Recent product-related developments, including regulatory approvals for PD-L1 tests, contributed to sentiment stability. Broader influences include ongoing laboratory spending patterns and the company’s upcoming third-quarter earnings announcement scheduled for late August.
Revvity (RVTY) Overview and Recent Performance
Revvity (RVTY) focuses on life sciences solutions, including reagents, instruments, and software for research, diagnostics, and applied markets. The stock posted stronger year-to-date performance of approximately 16.5% through late July 2026, outpacing some peers in the group. First-quarter 2026 revenue reached $711 million, up 7% year-over-year with a slight beat versus consensus. Management commentary highlighted improving momentum in key segments ahead of the second-quarter earnings call planned for early August. Recent activity also included sustainability updates and contract wins that supported steady investor attention.
Waters Corporation (WAT) Overview and Recent Performance
Waters Corporation (WAT) specializes in analytical instruments, particularly mass spectrometry and chromatography systems used in pharmaceutical, environmental, and clinical testing. Through late July 2026, year-to-date returns stood near 0.7%, while one-year performance reached about 30.7%. First-quarter results included revenue of $1.27 billion alongside an earnings beat. A recent product launch of a new clinical IVD mass spectrometer system provided a positive development in recent weeks. The company is scheduled to report second-quarter results in early August, with market focus on guidance and segment trends.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating suitability for prevailing market conditions receive placement in this section. Bots in the ecosystem span diverse trading styles, strategies, timeframes, and performance statistics, allowing users to review metrics such as win rates, drawdowns, and ticker-specific exposure before engaging. The platform provides transparent data on each bot’s historical results and operational parameters to support informed evaluation.
Head-to-Head Comparison
The three companies share exposure to life sciences instrumentation and diagnostics, yet differ in emphasis: Agilent Technologies (A) maintains a broad portfolio across chemicals and diagnostics, Revvity (RVTY) leans toward reagents and research tools, and Waters Corporation (WAT) concentrates on high-end mass spectrometry. Recent momentum has favored RVTY on a year-to-date basis, while WAT showed stronger longer-term returns. Risk factors include sensitivity to capital spending cycles in pharma and biotech, with valuation multiples reflecting growth expectations in those end markets. Sector sentiment remains tied to instrument replacement cycles and regulatory approvals rather than macroeconomic shifts alone. Trade-offs emerge in earnings visibility, with upcoming reports offering potential differentiation in reported organic growth and margin trends.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative year-to-date stability, and positioning ahead of earnings releases, Tickeron’s AI would currently assign a modestly higher probabilistic preference to Revvity (RVTY) within this group. The assessment reflects stronger recent returns and segment momentum indicators compared with peers, though all three exhibit comparable sector risks and catalysts. This view remains conditional on evolving data and does not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 3 FA rating(s) are green whileRVTY’s FA Score has 3 green FA rating(s), and WAT’s FA Score reflects 2 green FA rating(s).
- A’s FA Score: 3 green, 2 red.
- RVTY’s FA Score: 3 green, 2 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while RVTY’s TA Score has 5 bullish TA indicator(s), and WAT’s TA Score reflects 5 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 4 bearish.
- RVTY’s TA Score: 5 bullish, 3 bearish.
- WAT’s TA Score: 5 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +5.49% price change this week, while RVTY (@Medical Specialties) price change was +1.90% , and WAT (@Medical Specialties) price fluctuated +7.83% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
Reported Earning Dates
A is expected to report earnings on Aug 26, 2026.
RVTY is expected to report earnings on Nov 02, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | RVTY | WAT | |
| Capitalization | 41.2B | 12.8B | 39.9B |
| EBITDA | 1.96B | 773M | 991M |
| Gain YTD | 7.920 | 18.751 | 7.116 |
| P/E Ratio | 146.56 | 55.13 | 103.00 |
| Revenue | 7.23B | 2.9B | 3.77B |
| Total Cash | 1.81B | N/A | 462M |
| Total Debt | 3.36B | 3.35B | 5.57B |
A | RVTY | WAT | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 86 | 35 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 15 Undervalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 98 | 100 | 87 | |
SMR RATING 1..100 | 45 | 88 | 85 | |
PRICE GROWTH RATING 1..100 | 14 | 29 | 20 | |
P/E GROWTH RATING 1..100 | 4 | 19 | 4 | |
SEASONALITY SCORE 1..100 | 50 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is in the same range as RVTY (15) in the Medical Specialties industry, and is somewhat better than the same rating for WAT (75) in the Medical Specialties industry. This means that A's stock grew similarly to RVTY’s and somewhat faster than WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (87) in the Medical Specialties industry is in the same range as A (98) in the Biotechnology industry, and is in the same range as RVTY (100) in the Medical Specialties industry. This means that WAT's stock grew similarly to A’s and similarly to RVTY’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for WAT (85) in the Medical Specialties industry, and is somewhat better than the same rating for RVTY (88) in the Medical Specialties industry. This means that A's stock grew somewhat faster than WAT’s and somewhat faster than RVTY’s over the last 12 months.
A's Price Growth Rating (14) in the Biotechnology industry is in the same range as WAT (20) in the Medical Specialties industry, and is in the same range as RVTY (29) in the Medical Specialties industry. This means that A's stock grew similarly to WAT’s and similarly to RVTY’s over the last 12 months.
A's P/E Growth Rating (4) in the Biotechnology industry is in the same range as WAT (4) in the Medical Specialties industry, and is in the same range as RVTY (19) in the Medical Specialties industry. This means that A's stock grew similarly to WAT’s and similarly to RVTY’s over the last 12 months.
| A | RVTY | WAT | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 73% | 5 days ago 70% | 3 days ago 69% |
| Stochastic ODDS (%) | 3 days ago 62% | 3 days ago 71% | 3 days ago 72% |
| Momentum ODDS (%) | 3 days ago 62% | 3 days ago 62% | 3 days ago 63% |
| MACD ODDS (%) | 3 days ago 59% | 3 days ago 68% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 66% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 58% | 3 days ago 62% | 3 days ago 60% |
| Advances ODDS (%) | 3 days ago 60% | 11 days ago 64% | 5 days ago 62% |
| Declines ODDS (%) | 10 days ago 64% | 14 days ago 67% | 7 days ago 64% |
| BollingerBands ODDS (%) | 3 days ago 74% | 3 days ago 69% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 60% | 6 days ago 64% | N/A |
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | +0.37% | ||
| TMO - RVTY | 71% Closely correlated | +2.41% | ||
| A - RVTY | 65% Loosely correlated | +3.28% | ||
| CRL - RVTY | 65% Loosely correlated | +0.75% | ||
| WAT - RVTY | 64% Loosely correlated | +1.79% | ||
| AZTA - RVTY | 63% Loosely correlated | +4.23% | ||
More | ||||
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | +1.79% | ||
| A - WAT | 68% Closely correlated | +3.28% | ||
| RVTY - WAT | 64% Loosely correlated | +0.37% | ||
| TMO - WAT | 60% Loosely correlated | +2.41% | ||
| BRKR - WAT | 58% Loosely correlated | +4.17% | ||
| CRL - WAT | 56% Loosely correlated | +0.75% | ||
More | ||||